Cargando…

Neoadjuvant chemotherapy with Cisplatin in BRCA1 mutation carriers – results of treatment

Detalles Bibliográficos
Autores principales:	Byrski, T, Gronwald, J, Huzarski, T, Marczyk, E, Blecharz, P, Ashuryk, O, Cybulski, C, Zuziak, D, Wiśniowski, R, Godlewski, D, Narod, SA, Lubiński, J
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2012
Materias:	Meeting Abstract
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3395390/ http://dx.doi.org/10.1186/1897-4287-10-S3-A3

Ejemplares similares

Why choose the treatment with cisplatin for BRCA1 breast cancers patients?
por: Byrski, T, et al.
Publicado: (2012)

Neoadjuvant therapy with cisplatin in BRCA1-positive breast cancer patients
por: Byrski, T, et al.
Publicado: (2011)

Pathological complete response to neoadjuvant cisplatin in BRCA1-positive breast cancer patients
por: Byrski, Tomasz, et al.
Publicado: (2015)

Cisplatin in breast cancer treatment in BRCA1 carriers
por: Gronwald, Jacek, et al.
Publicado: (2012)

Folic acid and cancer risk in BRCA1 carriers
por: Durda, Katarzyna, et al.
Publicado: (2012)

Results of a phase II open-label, non-randomized trial of cisplatin chemotherapy in patients with BRCA1-positive metastatic breast cancer
por: Byrski, Tomasz, et al.
Publicado: (2012)

Selenium and the risk of cancer in BRCA1 carriers
por: Lubinski, J, et al.
Publicado: (2011)

Serum concentration of iron as predictor of cancer risk among BRCA1 mutation carriers
por: Sukiennicki, Grzegorz, et al.
Publicado: (2012)

Impact of BRCA1 mutation on survival after early onset breast cancer
por: Huzarski, T, et al.
Publicado: (2012)

Serum concentration of selected macro- and microelements and their correlation with the risk of breast and ovarian cancer among BRCA1 mutation carriers
por: Muszyńska, Magdalena, et al.
Publicado: (2012)

CHEK2 mutations as markers for high risk of breast cancer
por: Cybulski, Cezary, et al.
Publicado: (2012)

Vitamins A, E and D and cancer risk in BRCA1 carriers
por: Kąklewski, K, et al.
Publicado: (2012)

Selenium and genotypes as marker of risk in BRCA1 mutation carriers
por: Jaworska, K, et al.
Publicado: (2012)

Prospective observation of breast/ovarian cancer risk in BRCA1 carriers depending on serum selenium level optimized with diet
por: Lubiński, J, et al.
Publicado: (2012)

BRCA1 founder mutations and ovarian cancer in Belarus
por: Savanevich, A, et al.
Publicado: (2015)

BRCA1 and BRCA2 mutations in ovarian cancer patients from Belarus: update
por: Savanevich, Alena, et al.
Publicado: (2021)

The risk of breast cancer in women with a CHEK2 mutation
por: Cybulski, Cezary, et al.
Publicado: (2012)

A Lowering of Breast and Ovarian Cancer Risk in Women with a BRCA1 Mutation by Selenium Supplementation of Diet
por: Huzarski, Tomasz, et al.
Publicado: (2006)

Optimizing recruitment to a prostate cancer surveillance program among male BRCA1 mutation carriers: invitation by mail or by telephone
por: Galor, Anna, et al.
Publicado: (2013)

Cancer risks in first-degree relatives of CHEK2 mutation carriers: effects of mutation type and cancer site in proband
por: Gronwald, J, et al.
Publicado: (2009)

Pathological complete response after cisplatin neoadjuvant therapy is associated with the downregulation of DNA repair genes in BRCA1-associated triple-negative breast cancers
por: Domagala, Pawel, et al.
Publicado: (2016)

Recurrent mutations of BRCA1, BRCA2 and PALB2 in the population of breast and ovarian cancer patients in Southern Poland
por: Wojcik, P., et al.
Publicado: (2016)

Ovarian cancer risk in Polish BRCA1 mutation carriers is not associated with the prohibitin 3' untranslated region polymorphism
por: Jakubowska, Anna, et al.
Publicado: (2008)

Identification of patients at high risk of negative psychological consequences associated with BRCA1 mutation
por: Ertmański, S, et al.
Publicado: (2012)

Recurrent Mutations in BRCA1, BRCA2, RAD51C, PALB2 and CHEK2 in Polish Patients with Ovarian Cancer
por: Łukomska, Alicja, et al.
Publicado: (2021)

Frequency of BRCA1 and BRCA2 causative founder variants in ovarian cancer patients in South-East Poland
por: Kluz, Tomasz, et al.
Publicado: (2018)

Meeting abstracts from the Annual Conference on Hereditary Cancers 2016: Szczecin, Poland. 14-15 September 2016
por: Cybulski, C., et al.
Publicado: (2017)

BRCA1 founder mutations compared to ovarian cancer in Belarus
por: Savanevich, Alena, et al.
Publicado: (2014)

Screening with Magnetic Resonance Imaging in women at low and intermediate risk of breast Cancer
por: Huzarski, T T, et al.
Publicado: (2012)

Blood Arsenic Levels as a Marker of Breast Cancer Risk among BRCA1 Carriers
por: Marciniak, Wojciech, et al.
Publicado: (2021)

Association of recurrent mutations in BRCA1, BRCA2, RAD51C, PALB2, and CHEK2 with the risk of borderline ovarian tumor
por: Ogrodniczak, Alicja, et al.
Publicado: (2022)

Copper as diagnostic marker of cancers
por: Muszyńska, Magdalena, et al.
Publicado: (2015)

Magnesium as a diagnostic marker of cancer
por: Marciniak, Wojciech, et al.
Publicado: (2015)

Combined iPLEX and TaqMan assays to screen for 45 common mutations in Lynch syndrome and FAP patients
por: Dymerska, D, et al.
Publicado: (2011)

Population Screening of CHEK2 Mutations in Poland
por: Cybulski, Cezary, et al.
Publicado: (2006)

Selenium as diagnostic marker of cancers
por: Jaworska-Bieniek, Katarzyna, et al.
Publicado: (2015)

Zinc as diagnostic marker of cancers
por: Kaczmarek, Katarzyna, et al.
Publicado: (2015)

Iron as diagnostic marker of cancer
por: Sukiennicki, Grzegorz, et al.
Publicado: (2015)

Selenium (Se) and the risk of breast, ovarian and prostate cancers
por: Jaworska, Katarzyna, et al.
Publicado: (2012)

Genetic testing for hereditary breast cancer in Poland: 1998–2022
por: Gronwald, Jacek, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_47nlfknukk7u25pqo20snipvmq